← board
HEPA
distress 6/10 · elevated risk$0.050%today-44% from 52w high
Revenue
pre-revenue
Liquidity
$3M
Runway
1.6 yrs
Shares 1y
+151%
Price & events
-8.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-3.6%
1W
+3.9%
1M
+8.2%
3M
-8.6%
6M
+6.0%
1Y
-99.9%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $1.54M
- Volume
- 0
- 52 Week Range
- $0.04 – $0.10
- Total Shares
- 29.12M
- Float Shares
- 20.37M
- Short %
- 4.10%
- % Held by Insiders
- 38.64%
- % Held by Institutions
- 0.00%
- Beta
- 1.63
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.